Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) posted its quarterly earnings results on Monday. The company reported ($2.83) EPS for the quarter, missing analysts’ consensus estimates of ($2.16) by ($0.67), MarketWatch Earnings reports. Salarius Pharmaceuticals Stock Performance Shares of NASDAQ:SLRX opened at $2.08 on Tuesday. The firm has a fifty day moving average price of $2.28 […]
Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models Targeted protein degrader SP-3164 on track
HOUSTON HOUSTON Salarius Pharmaceuticals, Inc. (SLRX) on Monday reported a loss of $6.4 million in its fourth quarter. The Houston-based company said it…
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.